Nifu

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nifu

Quick Facts

Property Description
Active ingredient Niflumic Acid (Acidum niflumicum)
Form Capsule, Tablet, Suppository, Gel
Pharmacological class Non-Steroidal Anti-Inflammatory Drug (NSAID)
Common purpose Relief of pain, inflammation, and fever
Origin Synthetic organic compound

Nifu: Defining the Medicine and its Substance

Nifu is a common trade designation for a pharmaceutical product containing the active ingredient Niflumic Acid (Acidum niflumicum), which is the recognized International Nonproprietary Name (INN) for the substance. This is a single-ingredient product defined as a synthetic organic compound, meaning it is manufactured through chemical synthesis rather than being isolated from natural sources. Niflumic Acid is categorized within the fenamate group, a distinct chemical family of anti-inflammatory agents. This group is recognized for providing both systemic and local anti-inflammatory effects.


Classification and Presentation of Niflumic Acid

Niflumic Acid is formally classified within the high-level Non-Steroidal Anti-Inflammatory Drug (NSAID) pharmacological class. The NSAID class encompasses medicines that universally function to mitigate symptoms stemming from pain and inflammation. Niflumic Acid is supplied in various dosage form(s), a differentiating factor that allows for varied routes of administration. These forms include capsules and tablets for oral ingestion, suppositories for rectal use, and gels or creams designed for topical application directly to the skin.


General Purpose: How Nifu Helps

The general purpose of Nifu is to help manage the common symptoms of pain, inflammation, and fever that accompany various conditions. The medicine provides a combined therapeutic benefit: it is an analgesic (pain-relieving), anti-inflammatory, and antipyretic (fever-reducing) agent. Niflumic Acid works by inhibiting pathways related to inflammation and pain signaling. The medicine is designed to reduce discomfort and control swelling by tempering the body’s signaling mechanisms.

Regulatory References

  1. active ingredient
  2. Niflumic Acid
  3. fenamate group
  4. Non-Steroidal Anti-Inflammatory Drug (NSAID) pharmacological class
  5. analgesic
  6. anti-inflammatory
  7. antipyretic

What side effects are possible with Nifu?

Official Safety Profile and Adverse Reactions

The safety profile of Niflumic Acid, an NSAID, is structured in regulatory documents according to defined frequency categories and System-Organ Classes (SOC). This classification defines the officially documented adverse reactions based on their rate of occurrence.


Frequency Classification of Systemic Effects

Adverse reactions are most frequently classified as Common (may affect up to 1 in 10 people), primarily involving Gastrointestinal disorders such as abdominal pain and nausea. Effects classified as Uncommon (may affect up to 1 in 100 people) span several systems, including vomiting, diarrhea, headache, rash, and the potential for elevated liver enzymes or renal impairment.

Less frequent events are classified as Rare or Very Rare. Rare reactions may involve generalized allergic responses. Very rare documented effects include severe Haematological disorders (e.g., agranulocytosis) and specific Cardiac disorders such as heart failure.

Serious Adverse Reactions and Safety Constraints

The risk of gastrointestinal ulceration, haemorrhage, and perforation is officially documented as a serious adverse reaction associated with the NSAID class, including Niflumic Acid. These events are classified as rare or very rare but are considered clinically significant.

Official safety documents list specific constraints regarding use in certain groups. Older adults are noted to have an increased frequency of adverse reactions, particularly serious gastrointestinal events. The medicine is formally contraindicated in individuals with severe renal insufficiency and severe hepatic insufficiency. Furthermore, simultaneous use with other NSAIDs is officially not recommended due to the increased risk of complications, especially within the gastrointestinal tract.

Overdose and Emergency Response

Overdose and When to Seek Help

Any situation involving a suspected overdose of Nifu (Niflumic Acid) requires immediate medical attention. Official regulatory guidance mandates contacting a Poison Center or a healthcare provider promptly. Urgent help is required due to the risk of severe systemic complications documented for the Non-Steroidal Anti-Inflammatory Drug (NSAID) class.


Documented Manifestations and Risks

Overdose presentations, typically following an acute ingestion of an excessive amount, may involve central nervous system (CNS) effects such as dizziness, headache, and loss of coordination, along with nausea.

Severe or life-threatening outcomes are officially associated with acute NSAID toxicity. These documented risks include serious effects on the renal system (acute renal failure) and the CNS (convulsions or coma), as well as metabolic acidosis. This potential for system-wide compromise dictates the need for professional emergency care.


Management Strategy

The strategy for managing Nifu overdose is defined as symptomatic and supportive. This approach is required because official documents state that no specific antidotes are known for acute NSAID toxicity. Supportive measures aim to address specific clinical issues that arise.

As part of the initial response, regulatory information specifies rinsing the mouth; however, inducing vomiting is prohibited unless directed by a medical professional. Hospital monitoring may be required to facilitate supportive care and continuous clinical observation, particularly given the potential for severe, system-wide complications that need prompt intervention.

Therapeutic Uses of Nifu

Therapeutic Indications

Nifu is an intestinal antiseptic primarily used for the treatment of acute diarrhea suspected to be of bacterial origin. It is indicated for use in both adults and children, provided there is no suspicion of invasive phenomena such as a deterioration in general condition, fever, or signs of systemic infection.

Main Uses

The medication is utilized to address:

  • Acute Bacterial Diarrhea: It acts locally within the intestinal tract to inhibit the growth of susceptible microorganisms.
  • Intestinal Antisepsis: It serves as a localized treatment to reduce the bacterial load in the digestive system during acute episodes of diarrhea.

Benefits and Clinical Effects

The primary objective of treatment with Nifu is the restoration of normal bowel function. By targeting the bacterial cause of the digestive upset, the medication provides several clinical benefits:

  • Local Action: The active substance remains concentrated in the intestinal lumen, exerting its effect directly at the site of infection with minimal systemic absorption.
  • Symptom Management: It aids in reducing the frequency and fluidity of stools when used as a complement to dietary measures and rehydration.
  • Preservation of Intestinal Flora: Unlike some broad-spectrum systemic antibiotics, it focuses on common intestinal pathogens while minimizing impact on the broader microbial balance.

Role in Comprehensive Care

While Nifu addresses the infectious component of diarrhea, its use is considered part of a broader management strategy. This includes the essential practice of rehydration—adjusting fluid and electrolyte intake based on the severity of the diarrhea, age, and individual patient needs. The treatment aims to shorten the duration of the episode and prevent complications associated with bacterial overgrowth in the gut.

Eligibility and Restrictions for Use

Who Can and Cannot Use Nifu? — Official Regulatory Information

The eligibility for Nifu is strictly defined by regulatory authorities, with specific populations formally excluded from using the medicine.

Eligibility Status Population Restriction (Regulatory Basis)
Contraindicated Patients with a known hypersensitivity or severe allergic reaction to the active substance (Nifu) or any of the product's inactive components.
Contraindicated Individuals with severe hepatic impairment (e.g., Child-Pugh Class C) or severe renal impairment (e.g., eGFR less than 30 mL/min).
Contraindicated Pregnant women and breastfeeding women, as formally stated in the official Use in Specific Populations sections.
Not Recommended Pediatric patients (children and adolescents) under 18 years of age, as safety and effectiveness have not been established in this age group.

The regulatory documents establish absolute contraindications for use in individuals who have an allergy risk, pre-existing severe organ dysfunction, or who are pregnant or lactating. Use is otherwise permitted only in patients who meet the approved indication and who are at least 18 years old, provided none of the contraindications are present. These official limitations define the definitive patient population that must not receive Nifu due to risks that clearly outweigh potential benefits in those groups.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Nifu (Niflumic Acid) is officially documented to interact with several classes of medicinal products, primarily through two high-level patterns: pharmacodynamic risk intensification and pharmacokinetic exposure modification. These documented interactions stem directly from its regulatory profile as a Non-Steroidal Anti-Inflammatory Drug.


Official Interaction Statements

  • Anticoagulants and Antiplatelets: Co-administration with agents such as Warfarin is documented to increase the risk and severity of bleeding and hemorrhage due to additive effects on hemostasis.
  • Other NSAIDs/Acetylsalicylic Acid: The risk of serious gastrointestinal adverse events (e.g., bleeding and ulceration) is intensified, resulting in a regulatory restriction against routine co-administration with other systemic NSAIDs or high-dose Acetylsalicylic Acid.
  • Lithium and Methotrexate: Nifu may significantly increase the plasma concentrations of both Lithium and Methotrexate by reducing their renal clearance, leading to a risk of toxicity.
  • Antihypertensives and Diuretics: Nifu may decrease the efficacy of Antihypertensive Agents and Diuretics, which can also increase the risk of renal failure, hyperkalemia, and hypertension.

Interaction Context and Restrictions

Classification Constraint
Population-Specific Risk The elderly are at greater risk for serious gastrointestinal adverse events associated with pharmacodynamic interactions.
Timing-Based Rules No mandatory timing rules requiring specific separation of administration are explicitly documented.

The regulatory profile defines this drug's interaction structure primarily through Pharmacodynamic Risk Intensification, which mandates caution with agents affecting blood clotting, and Pharmacokinetic Reduction of Clearance, which highlights the need to monitor systemic exposure for renally cleared agents.

Mechanism of Action

Nifu acts as an inhibitor targeting the Signal Transducer and Activator of Transcription 3 (STAT3) protein. The molecule blocks both constitutive and inducible STAT3 activation, with specific evidence for inhibition of activation mediated by interleukin-6 (IL-6) signaling.

At the molecular level, this inhibition disrupts the upstream cascade that leads to STAT3 phosphorylation and subsequent dimerization. Consequently, the translocation of the activated STAT3 dimer to the cell nucleus is blocked. This intracellular event prevents the DNA binding of STAT3, thereby modulating the transcription of target genes typically regulated by this factor. Downstream consequences include the induction of G2/M cell cycle arrest and the subsequent triggering of apoptosis in susceptible cell populations. These cellular effects result in a systemic modulation of cell proliferation rates within affected tissues.

Dosage and Administration Information

How Nifu is Used: Official Administration Guidelines

Nifu, containing the active substance Niflumic Acid, is administered according to a protocol that accommodates two distinct delivery methods based on the dosage form. The official routes are oral administration, using tablets or capsules for systemic action, and topical application, utilizing gels or creams for localized effects.


Systemic (Oral) Administration

The standardized adult regimen is based on a 250 mg unit dose. This dose is taken in divided portions throughout the day, typically three or four times daily. Guidelines specify the upper limit for oral intake, clarifying that the total daily dosage must not exceed 1500 mg. This structured frequency and dose maximum define the official high-level use pattern for the systemic form.


Localized (Topical) Application

For topical use, formulations such as the 2.5% or 3% gels and creams are intended to be applied directly to the affected area. This application is generally scheduled for two to three times per day, providing localized administration without the systemic constraints of oral dosing. All administrations, regardless of route, are prescribed under the supervision of a qualified professional and are typically intended for the shortest duration necessary to address the condition.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Nifu

Evidence for Use in Chronic Musculoskeletal Discomfort

This section will summarize the structure of research evidence, including short-term Randomized Controlled Trials (RCTs), that have evaluated Niflumic Acid's symptomatic role in chronic conditions like osteoarthritis and rheumatoid arthritis, detailing the specific pain and functional outcomes that were studied.

Studies relevant to this area were conducted, with research examining how symptoms change over time in patients dealing with chronic joint conditions. The research monitored outcomes related to outcomes related to physical discomfort, such as changes in pain intensity, and outcomes reflecting daily functioning. The findings describe patterns observed in the studies where pain and functional measurements changed over the limited time they were observed. This evidence contributes to the broader evidence landscape supporting the use of the NSAID class in conditions characterized by functional limitations. However, the follow-up durations were limited, and long-term effects are not fully established.

Evidence for Use in Acute Pain and Post-Injury Inflammation

Nifu was studied for its potential role in managing outcomes describing episodic or acute changes in pain intensity following events such as soft tissue injuries. Research examined how rapidly pain scores changed, and studies explored the impact on outcomes linked to inflammatory or irritative states through measurements of localized swelling. The data show patterns related to changes in measurements of outcomes related to physical discomfort during these acute, short-term research scenarios. A research gap is that comparative evidence is lacking in large-scale trials directly comparing Niflumic Acid to all other standard analgesic options for every type of acute pain scenario.

Research Gaps and What Remains Uncertain About Nifu

Across the range of indications, several research limitations are apparent. The duration of most clinical trials is limited, meaning that long-term effects are not fully established, particularly concerning the management of chronic conditions. Furthermore, evidence quality varies across studies, and sample sizes were modest in some trials. Data for certain groups, such as older adults or those with complex pre-existing health issues, remain insufficient. Overall, the evidence helps show what has been observed so far but research does not determine whether an individual will respond similarly, underscoring that research is ongoing in the broader NSAID category.

Key Studies & References

  1. Antiseizure properties of fenamate NSAIDs determined in mature human stem-cell derived neuroglial circuits
  2. Patient Walking Rehabilitation Program with osteoarthritis of the hip or knee helped by a one-off anti-inflammatory treatment (PERIPATEI) [Clinical Trial Summary]

Frequently Asked Questions (FAQ)

Common questions about Nifu (FAQ)


Q: Is Nifu an antibiotic or an anti-inflammatory?

A: Official regulatory documents classify Nifu (Niflumic Acid) as a Non-Steroidal Anti-Inflammatory Drug (NSAID). This means its primary purpose is to provide anti-inflammatory, pain-relieving (analgesic), and fever-reducing (antipyretic) effects. It is not an antibiotic.


Q: How quickly should I expect to feel the effects of Nifu?

A: Studies and official information indicate that the substance reaches its highest concentration in the bloodstream, a measure called Maximum Plasma Concentration (Tmax), typically in under three hours following an oral dose. This peak level generally represents the maximum concentration of the substance, which is thought to relate to when the medicine's main effects are most noticeable, although the actual time to feel relief can vary greatly from person to person.


Q: How long does Nifu stay in your system after you stop taking it?

A: The length of time a medicine remains in the system is estimated using its elimination half-life (t1/2). The half-life represents the time needed for the body to reduce the amount of the drug by half. The total time it takes for the substance to clear the system is influenced by individual factors, such as liver and kidney function.


Q: Are there any specific foods I should avoid while taking Nifu?

A: While regulatory information may not list specific restricted foods, some oral formulations of Niflumic Acid are officially recommended to be taken with or after a meal. This suggestion is typically included to help reduce the possibility of gastrointestinal side effects, such as irritation, and may also be related to optimizing how the substance is absorbed.


Q: What happens if I miss a dose of Nifu?

A: Regulatory guidelines often state that if a dose is missed, individuals should not take two doses at once but should instead refer to the instructions on how to proceed with the next scheduled dose. This ensures consistency with the official prescribing information.


Q: Can Nifu cause skin reactions or rashes?

A: Yes, official product information documents that rash and other skin reactions are known adverse effects of Nifu. These are typically classified as Uncommon, meaning they may affect up to 1 in 100 people. Any persistent or severe skin reactions should be brought to the attention of a qualified healthcare professional.


Q: Is the effectiveness of Nifu reduced by alcohol?

A: Official drug information focuses primarily on the increased safety risk when consuming alcohol with Nifu, noting that it can enhance the risk of serious gastrointestinal side effects, such as bleeding and ulceration. This safety risk is the main concern documented in regulatory texts.


Q: Can Nifu be taken on an empty stomach?

A: Regulatory labeling often specifies the preferred way to take the medicine. For oral NSAIDs like Nifu, administration is frequently directed to be taken with food to reduce the risk of irritation or damage to the stomach lining. Taking it on an empty stomach could potentially increase this risk, which is why official administration instructions should always be followed.


Q: Is there a maximum amount of time someone should continuously take Nifu?

A: Yes, official regulatory guidelines stress that NSAIDs should be used at the lowest effective dose for the shortest duration necessary. This precaution is specifically intended to minimize the potential risk of serious adverse reactions, particularly those affecting the cardiovascular and gastrointestinal systems, which can increase with prolonged use.


Q: Does Nifu make you more sensitive to the sun?

A: Some skin reactions are known adverse effects of Nifu. While regulatory documents list various skin issues, the presence of photosensitivity (increased sensitivity to sunlight) is typically addressed in the Warnings and Precautions section of the official product label.


Q: Does Nifu have an effect on mood or anxiety?

A: Official adverse reaction lists focus on frequently observed events, such as headache, which is common among Central Nervous System (CNS) effects. Mood disturbances like depression or anxiety are sometimes documented for NSAIDs, but they are typically classified as Rare or Very Rare events, according to the official adverse reaction lists.


Q: What should I do if the side effects from Nifu don't go away?

A: Official patient information consistently instructs that if side effects are persistent, worsen, or cause concern, they should prompt contact with a qualified healthcare professional immediately. This ensures that the appropriate medical guidance and follow-up are provided.


Q: Can Nifu interact with common supplements like magnesium or iron?

A: Regulatory documents list established drug-to-drug interactions. While specific mineral supplements may not always be listed, it is important that prescribers are made aware of all supplements being taken, as NSAIDs can affect the absorption or excretion of other co-administered substances.


Q: Is Nifu known by any other names or brand names globally?

A: Yes, the official substance name is Niflumic Acid (the International Nonproprietary Name, or INN). This active ingredient is then marketed and sold under a variety of different brand names in different countries around the world.


Q: Why is the dosage of Nifu sometimes different for the same condition?

A: Official dosing guidelines provide a recommended range, not a single fixed number. This flexibility allows a prescriber to adjust the dose within the regulatory limits based on the severity of the patient's condition and the individual response to the treatment.


Q: How does Nifu actually target the body's [mechanism/disease]?

A: According to the official mechanism of action, Nifu works by inhibiting specific cellular targets, such as cyclooxygenase (COX) enzymes. This action ultimately leads to the disruption of the body’s signaling pathways, resulting in the reduction of pro-inflammatory substances like prostaglandins.


Q: What are the typical clinical trial results for Nifu's effectiveness?

A: Regulatory documents include a summary of the clinical efficacy data, which outlines the observations from studies like Randomized Controlled Trials (RCTs). This summary details the measured outcomes related to pain relief and functional improvement that were observed across the patient groups studied.


Q: Does Nifu come in different forms (e.g., tablet, capsule, liquid)?

A: Official pharmaceutical information confirms that Niflumic Acid is available in several regulatory-approved forms. These typically include oral capsules or tablets, and sometimes suppositories and topical gels or creams for localized application.

How should Nifu be stored and disposed of?

How to Store and Dispose of Nifu?

This section outlines the mandatory storage and disposal instructions for Nifu (Niflumic Acid) as defined by official regulatory labeling.


Storage Requirements

Nifu tablets must be stored at room temperature, generally between 68 F and 77 F. The medicine must be kept in its container and protected from light and moisture, requiring the bottle to be kept tightly closed in a dry location. It is a mandatory requirement that Nifu be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Nifu must not be discarded in household trash, flushed down the toilet, or allowed to enter public sewers or waterways. Due to its environmental hazard classification, disposal must adhere to local regulations for pharmaceutical waste. This often requires utilizing an approved drug take-back program or delivering the product to a designated waste facility.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nifu found in:

A-Z Index: